Hologic (NSDQ:HOLX) reported third-quarter earnings this evening that beat the consensus forecast on Wall Street, raising its full-year guidance.
The Marlborough, Mass.–based women’s health medtech company reported profits of $93.9 million, or $0.35 per share, on sales of $852.4 million for the three months ended June 29, for a bottom-line decrease of 16.8% and sales growth of 3.4% compared with Q3 2018.
Adjusted to exclude one-time items, earnings per share were $0.63, 2¢ ahead of The Street. Excluding Hologic’s divested Blood Screening business, revenue was $838.2 million — ahead of the $835.74 million predicted by analysts.
Hologic CEO Steve MacMillan said the company’s new pipeline of products continues to grow.
“Growth was driven by our Molecular Diagnostics and Breast Health businesses, which continued their strong recent trends. In addition, the performance of our Surgical business continues to improve,” MacMillan said in a news release.
Hologic said it expects to log adjusted EPS of $2.42 to $2.44 this year, a slight improvement from prior guidance of $2.41 to $2.44. The company also increased its top-line outlook to $3.335 billion to $3.350 billion, compared with $3.325 billion to $3.345 billion previously.